Company intelligence / Profile preview
Regencor
San Mateo (HQ), California, United Statesregencor.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Regencor’s lead program REG101 has demonstrated regenerative properties in several large animal studies by stimulating the proliferation of cardiomyocytes after MI. The company reports compelling preclinical data showing reversal of scar tissue formation and restoration of contractile function. No human clinical results yet; IND-enabling studies are ongoing with first-in-human trials planned for late 2025
- Therapeutic areas
- Cardiovascular
- Modalities
- Recombinant protein therapeutics (specifically REG101, a proprietary biologic/protein)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Regencor.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Regencor.